Publication Name	World Journal of Stem Cells
Manuscript ID	71533
Country	Indonesia

Received	2021-09-11 11:28
Peer-Review Started	2021-09-11 11:30
To Make the First Decision
Return for Revision	2021-11-17 08:22
Revised	2021-11-23 05:00
Second Decision	2022-03-01 05:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-03-07 00:09
Articles in Press	2022-03-07 00:09
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-02-25 22:02
Typeset the Manuscript	2022-03-21 01:22
Publish the Manuscript Online	2022-03-25 07:41

ISSN	1948-0210 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Respiratory System
Manuscript Type	Letter to the Editor
Article Title	Mesenchymal stem/stromal cells as adjuvant therapy in COVID-19-associated acute lung injury and cytokine storm: Importance of cell identification
Manuscript Source	Invited Manuscript
All Author List	Jeanne Adiwinata Pawitan
ORCID	Author(s) ORCID Number Jeanne Adiwinata Pawitan http://orcid.org/0000-0002-6551-5238
Funding Agency and Grant Number
Corresponding Author	Jeanne Adiwinata Pawitan, MD, PhD, Professor, Department of Histology, Faculty of Medicine, Universitas Indonesia, Gedung Anatomi, Jl. Salemba 6, Jakarta 10430, DKI Jaya, Indonesia. jeanneadiwip@gmail.com
Key Words	COVID-19; Mesenchymal stem cells; Pneumonia; Cytokine storm; Acute respiratory distress syndrome
Core Tip	Several published studies, which used mesenchymal stem cells (MSCs) to alleviate coronavirus disease 2019 associated acute lung injury and cytokine storm, reported promising results. However, the evidence came from a case report, case series, and clinical trials with limited number of participants. Therefore, more robust proofs are needed. The studies and on-going clinical trials used MSCs from various sources, and theoretically, angiotensin-converting enzyme 2 negative subsets are preferable. Therefore, in future reporting of clinical trial results, the complete identity of the MSCs needs to be defined.
Publish Date	2022-03-25 07:41
Citation	Pawitan JA. Mesenchymal stem/stromal cells as adjuvant therapy in COVID-19-associated acute lung injury and cytokine storm: Importance of cell identification. World J Stem Cells 2022; 14(3): 264-266
URL	https://www.wjgnet.com/1948-0210/full/v14/i3/264.htm
DOI	https://dx.doi.org/10.4252/wjsc.v14.i3.264

Full Article (PDF)	WJSC-14-264.pdf
Full Article (Word)	WJSC-14-264.docx
Manuscript File	71533_Auto_Edited-JRF-Filipodia CL.docx
Answering Reviewers	71533-Answering reviewers.pdf
Audio Core Tip	71533-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	71533-Conflict-of-interest statement.pdf
Copyright License Agreement	71533-Copyright license agreement.pdf
Peer-review Report	71533-Peer-review(s).pdf
Scientific Misconduct Check	71533-Bing-Fan JR-2.png
Scientific Editor Work List	71533-Scientific editor work list.pdf